Discover insights from Corcept Therapeutics' Q1 2025 earnings call: revenue growth, relacorilant's FDA review, and its strategic outlook ...

Q1 2025 Management View CEO Sumit Roy highlighted the company’s diversified global portfolio comprising 65% U.S. retail and ...

Good day, everyone, and welcome to Neurocrine Biosciences Reports First Quarter 2025 Results. At this time, all participants are in a listen only mode. Later, you will have the opportunity to ask ...

Hims & Hers Health (NYSE:HIMS) reported a strong financial performance for Q1 2025, with revenue reaching $586 million, ...

Q1 2025 Management View CEO Jim Farley highlighted strong underlying business performance, including achieving the best first ...